Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Tumefactive Demyelination, an Uncommon Form of Tacrolimus Neurotoxicity
Neurol 76:672-674, Kim,S.H.,et al, 2011
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Sirolimus-Induced Posterior Reversible Encephalopathy
Neurol 68:2039-2040, Bodkin,C.L. &Eidelman,B.H., 2007
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
NEJM 354:980-982, Ozcan,C.,et al, 2006
Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006
Reversible Posterior Leukoencephalopathy Syndrome
Intern Med J 35:83-90, Stott,V.L.,et al, 2005
Treatment-Induced Leukoencephalopathy in Primary CNS Lymphoma,A Clinical and Autopsy Study
Neurol 62:451-456, Lai,R.,et al, 2004
Tacrolimus Leukoencephalopathy: A Neuropathologic Confirmation
Neurol 63:1132-1133, Lavigne,C.M.,et al, 2004
Severe Neurologic Complications After Hematopoietic Stem Cell Transplantation in Children
Neurol 59:1895-1904,E13, Farci,M.,et al, 2002
Reversible Posterior Leukoencephalopathy During the Treatment of Acute Lymphoblastic Leukemia
Neurol 56:388-391, Shin,R.K.,et al, 2001
Reversible Tacrolimus-Induced Neurotoxicity Isolated to the Brain Stem
AJNR 21:1251-1254, Oliverio,P.J. et al, 2000
Neurologic Complications of Pediatric Lung Transplantation
Neurol 53:1542-1549, Wong,M.,et al, 1999
Cerebral Vasculitis During FK 506 Treatment in a Liver Transplant Patient
Neurol 50:1154-1157, Pizzolato,G.P.,et al, 1998
A Reversible Posterior Leukoencephalopathy Syndrome
NEJM 334:494-500, Hinchey,J.,et al, 1996
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Neuroimaging Findings in Patients on Immunosuppressive Therapy:Experience with Tacrolimus Toxicity
AJR 166:683-688, Appignani,B.A.,et al, 1996
Immunosuppression-Induced Leukoencephalopathy from Tacrolimus (FK506)
Ann Neurol 40:575-580, Small,S.L.,et al, 1996
Causes and Outcome of Seizures in Liver Transplant Recipients
Neurol 47:1523-1525, Wijdicks,E.F.M.,et al, 1996
Neurotoxicity in Liver Transplant Recipients with Cyclosporine Immunosuppression
Neurol 45:1962-1964, Wijdicks,E.F.M.,et al, 1995
MR Imaging of Reversible Cyclosporin A-Induced Neurotoxicity
AJR 157:851-859, Truwit,C.L.,et al, 1991
Cyclosporine-Related Central Nervous System Toxicity in Cardiac Transplantation
NEJM 323:420-421, Hughes,R.L., 1990
Current Concepts in the Idiopathic Inflammatory Myopathies:Polymyositis, Dermatomyositis, and Related Disorders
Ann Int Med 111:143-157, Plotz,P.H.,et al, 1989
Azathioprine Toxicity in Neuromuscular Disease
Neurol 36:35-39, Kissel,J.T.,et al, 1986
Central Nervous System Infection in the Chronically Immunosuppressed
Medicine 61:166-188, Hooper,D.C.,et al, 1982
Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis
NEJM 301:235-238, Fauci,A.S.,et al, 1979
Current Concepts in Cancer-Brain Tumors
NEJM 300:1469-1471, Wilson,C.B., 1979
Infectious Complications of Neoplastic Disease
Med Clin North Am 55:729, Armstrong,D.,et al, 1971
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis,A Systematic Review
JAMA Neurol 82:193-199, Terrim,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Immunosuppressive Therapy Reversing Obstructive Hydrocephalus in CLIPPERS
Neurol 102:e209396, Yang,Y.,et al, 2024
Herpes Simplex Virus Encephalitis in Patients with Autoimmune Conditions or Exposure to Immunomodulatory Medications
Neurol 102:e209297, Tang,A.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Pregnancy in Patients with AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Neurol 96:e2006-e2015, Collongues, N.,et al, 2021
Clinicopathologic Conference, Cerebral Amyloid Angiopatny-Related Inflammation
NEJM 385:358-368, Case 22-2021, 2021
A 47-Year-Old With Headache, Vertigo, and Double Vision
Neurol 97:e535-e539, Frey, J.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020